Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles ACS Medicinal Chemistry Letters Year : 2019

Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling

Abstract

Dissymmetric cross metathesis of alkenes as a convergent and general synthetic strategy allowed for the preparation of a new small series of human histone deacetylases (HDAC) inhibitors. Alkenes bearing Boc-protected hydroxamic acid and benzamide and trityl-protected thiols were used to provide the zinc binding groups and were reacted with alkenes bearing aromatic cap groups. One compound was identified as a selective HDAC6 inhibitor lead. Additional biological evaluation in cancer cell lines demonstrated its ability to stimulate the expression of the epithelial marker E-cadherin and tumor suppressor genes like SEMA3F and p21, suggesting a potential use of this compound for lung cancer treatment. Molecular docking on all 11 HDAC isoforms was used to rationalize the observed biological results.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02265954 , version 1 (13-08-2019)

Identifiers

Cite

Samuel Bouchet, Camille Linot, Dusan Ruzic, Danica Agbaba, Benoit Fouchaq, et al.. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Medicinal Chemistry Letters, 2019, 10 (6), pp.863-868. ⟨10.1021/acsmedchemlett.8b00440⟩. ⟨inserm-02265954⟩
72 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More